Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2

Digestive and Liver Disease

Volumn 48, Issue 4, 2016, Pages 435-440

  Lee, Sang Hoon ^a   Yoon, Sang Hyun ^a   Lee, Hee Seung ^a   Chung, Moon Jae ^a   Park, Jeong Youp ^a   Park, Seung Woo ^a   Song, Si Young ^a   Chung, Jae Bock ^a   Bang, Seungmin ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biguanide; Pancreatic adenocarcinoma; Survival

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CA 19-9 ANTIGEN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG USE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT DURATION; UNIVARIATE ANALYSIS; BLOOD; CANCER STAGING; COMPLICATION; DIABETES MELLITUS, TYPE 2; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SOUTH KOREA; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84960812933     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.12.006     Document Type: Article

References (20)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 2014, 64:9-29.
2. DeSantis C.E., Lin C.C., Mariotto A.B., et al. Cancer treatment and survivorship statistics, 2014. CA: A Cancer Journal for Clinicians 2014, 64:252-271.
3. Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. New England Journal of Medicine 2014, 371:1039-1049.
4. Huxley R., Ansary-Moghaddam A., Berrington de Gonzalez A., et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British Journal of Cancer 2005, 92:2076-2083.
5. Pannala R., Leirness J.B., Bamlet W.R., et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008, 134:981-987.
6. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
7. Wang Z., Lai S.T., Xie L., et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Research and Clinical Practice 2014, 106:19-26.
8. Li D., Yeung S.C., Hassan M.M., et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
9. Pernicova I., Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nature Reviews Endocrinology 2014, 10:143-156.
10. Zakikhani M., Dowling R., Fantus I.G., et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research 2006, 66:10269-10273.
11. Lappano R., Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nature Reviews Drug Discovery 2011, 10:47-60.
12. Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Current Opinion in Cell Biology 2005, 17:596-603.
13. Bao B., Wang Z., Ali S., et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevention Research (Phila) 2012, 5:355-364.
14. Hirsch H.A., Iliopoulos D., Tsichlis P.N., et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Research 2009, 69:7507-7511.
15. Kisfalvi K., Moro A., Sinnett-Smith J., et al. Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas 2013, 42:781-785.
16. Sadeghi N., Abbruzzese J.L., Yeung S.C., et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:2905-2912.
17. Hwang A.L., Haynes K., Hwang W.T., et al. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas 2013, 42:1054-1059.
18. Choi Y., Kim T.Y., Oh D.Y., et al. The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Research and Treatment 2015.
19. Zhang J.W., Sun Q. Metformin may improve the prognosis of patients with pancreatic cancer. Asian Pacific Journal of Cancer Prevention 2015, 16:3937-3940.
20. Kordes S., Pollak M.N., Zwinderman A.H., et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology 2015, 16:839-847.